{"name":"PX'Therapeutics","slug":"px-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNaEliRnFLWjdkb2RUUnU0ek0tVEJvSXFKcGVZTWV1dmR6N2tRajBKeFRZY3NYTjJHUHFkdm1iUklKa25jN2lmeHR5emgtNEVoTHJORUxyLUJ0Ym82Ym9pU2VESzdLSVloWklzZXQtWjhycE0wZmU1Tlp2akt6OVpvYWl0RUdoNUJ3YTM1bExHX1NMNUV5cWNOb3JSR1Y0eGp0em04M0JiUXJHbFVXaEFlRWl0OWdCVG1sNW93Y0dVYWsyWUlsVFc5M1ZhaUY1SDd4RG9JWnh3?oc=5","date":"2026-04-06","type":"earnings","source":"GlobeNewswire","summary":"Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement - GlobeNewswire","headline":"Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"regulatory","source":"simplywall.st","summary":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed? - simplywall.st","headline":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPQ25xQTA1VkFzVGgyaFQtWDlKRGZ6TlBxU0pmV3duREQyRlhycmNpRGF5SlJ6R1NfOGxHTXF1OE9fUFlKYzV3Wl9laGI5UzM0ZmhyMnAzc2U5bmxWUmZIbXVNNUpXc1Q2cnJjRVBTdnBPTGJwQnhPTFRrNDFwVUZDZEJuNHNFV0JmSk1SR3RZWjR0Zl9nNl9obHhuaUFHZzlEVV91dTcxWXgwU2ltTEItQUhsdmg3YloxbmRpUnBjRS1UQ2NoZmZqQQ?oc=5","date":"2026-03-24","type":"trial","source":"AD HOC NEWS","summary":"Telix Pharmaceuticals Ltd stock gains momentum on ASX amid radiopharma trial updates and valuation r - AD HOC NEWS","headline":"Telix Pharmaceuticals Ltd stock gains momentum on ASX amid radiopharma trial updates and valuation r","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-23","type":"trial","source":"simplywall.st","summary":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates - simplywall.st","headline":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPRkYyajNfWE1tTmN0bUV2VFkzdGFTalBpdUZ4M1VtbXBSSGs0N2JQa1RIYml6Rm5OTW1pNXY2NEdmVlU3SkZQYzlqT3hvZEh3YVJpSHZ0WWhXYVgwSW5UYnB0ZWVpSHFPNkNmaUk4dXBBZVpYS2t3RE91S3ZFZjRCQmE3enhMc2lSNHQwMHpFcWRKUngxdWotMmszc21zWGRLV0hpQXdBNjVJQThDVndkd2JvdmE?oc=5","date":"2026-03-16","type":"regulatory","source":"The Motley Fool Australia","summary":"Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent - The Motley Fool Australia","headline":"Telix Pharmaceuticals resubmits FDA application for brain cancer imaging agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNN09xc0VnNEV2bVEzZUJXdFQxMWN3d1VVN1RscFJSY2hrQ0poaEVJajF3ZERwTWVpZnlwM2dsZGVHYW9FWlJqeGl5OHJOSEgzeUZNYlpSUnVycHZBTW0yM1FvWTBxQVNtWkRrWWhWMzhQX1BCa0VCZXlhM0dVaDFza1d4RWNMcXZhNFRkRkItVTFManU2NVN5NGNpYjVva19xNmZlYzk2SXZ0bnc3ckFBOUktTkNpRjZuM3Jfd014YlZCZ2VJRVYyVUU4Wk42b1huRXFUcGI4UkVjVi1hcGJEZnVqSVc0b1RheUFlVg?oc=5","date":"2026-03-15","type":"regulatory","source":"GlobeNewswire","summary":"Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate - GlobeNewswire","headline":"Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPdEJsZWViLVVXRWE0WlZtT0lMSHRUY2dvaGhWeVI3cENsWnBaSmdUZmdQbVZCWi1McXIxYWIwVDRKSW1iT29OZlJsREd2MmI5VHpoZm5pN3FOdzZMTzktSnhteTJzaXVyQXNPcXQzNTJ0S05oM3JHa2traGltbDRua3k4ajgtdw?oc=5","date":"2026-02-22","type":"pipeline","source":"Yahoo Finance","summary":"Why Telix Pharmaceuticals (ASX:TLX) Is Up 19.1% After 2026 Guidance, Shelf Filing And TLX101-Px Milestone – And What's Next - Yahoo Finance","headline":"Why Telix Pharmaceuticals (ASX:TLX) Is Up 19.1% After 2026 Guidance, Shelf Filing And TLX101-Px Milestone – And What's N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOWmRCMk9hVWt0UjNjWkZJaDVEd0VGV0U1SW11ZzlscWtWRGROZnJRbzRCd1Y5N3gwRzM4aWtaZHJieDM1ejI0UzZ2c0g2V3NRYk11aVVZcEV5b2ZDUVJIaWtWWUk0V2U5QjVqUjd2WWJqQV93T2JGVUhGZWFfNlFpVkt6WXVuZEt2bnR4UDEyV201ZHdZNmY5OE5lZVk1QW5PZllwckc1ODFQM096SGMtYWJvcw?oc=5","date":"2026-02-18","type":"regulatory","source":"Biotech Dispatch","summary":"Telix files for European approval of brain cancer imaging candidate TLX101-Px - Biotech Dispatch","headline":"Telix files for European approval of brain cancer imaging candidate TLX101-Px","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQMF9BWXpOYmhub0RzMmNsVWpKak9ibzhFQWVPWmxMR3hJN0RQamdXRzFMbTB4QlV2dkFxZ1h3UTBlQ3EwNmF5MTd5dW9OU1QwdHZUNGJvRDFNTktwbzdMaVFubE9lVHUtZGs5aDlQNGplRVpleXlRR1N3aHBoZFJLTVp1LThxZlk4N2hrdkhxWkhQWjROTlk0UWZuT2RaVHdHSjNDWXVJb01GZTRoRTVMZjJrcUFONWs?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"New Telix brain scan aims to distinguish tumor growth from treatment effects - Stock Titan","headline":"New Telix brain scan aims to distinguish tumor growth from treatment effects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNaV92YkR2cy1XUER5UFBjeEtFNVB4Z1N6SExuWlhkaUhrRzRDYXQ3dGJVTHU4Q1AtdmF0OEQyc0lVNnBOWXk0OVV0SENPNWRtbERhblB5ZnNYVTNycm5YcnVNc2JhZDlyYjM0elhEZWN0QXpyZ1h4dWJVb18zSVdVU1REMjVhQQ?oc=5","date":"2026-01-30","type":"trial","source":"Medical Device Network","summary":"Telix doses first patient in TLX591-Px prostate imaging trial - Medical Device Network","headline":"Telix doses first patient in TLX591-Px prostate imaging trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxQdHU3NS1sX0ZONFJHcjFubnhiaklRTF9VRUJqSkcyN1pFN19PeWVIV3BhVWZMNHV3RFY3Qk9Ka3Bkc3hwN0R1U1NEdzROenlzV0dFM0tCNkdORHlaWS0wVlIyVTNGS3FTVXBKYlBkNnQwSmJSQmJWcDczUXRFb0w4OUp3dUNmT3Nva3JrazgtVHA4RTRoLWtOTUlfaTNBRWs5WXpFd1UyM2VVRHZabVZhZEJVUGFaT2ZmT0JEbDBRWUs0QlFhWngyY0xnaTA1OE0zR2VCRmdWaEFLblZBbHNUQmZvTVdyLVJyTmMyY3gzTUNvbWZPalJhREFXdjlwb0wzWVFIRXljOA?oc=5","date":"2026-01-29","type":"trial","source":"PR Newswire","summary":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients - PR Newswire","headline":"First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQNWdwbkNza3ZRTU91eDFDQk9wN1JxUWVmT012N0VZbFBqSUFaNGFSOFlnMjdwMzkta2h3SHdKVzRQSFZCWXhVeGZEY09naFctRFRoZDcxczl6QUUwVm4tZElydnFna0VSS0x1RHQ2S191eGhyTFoxT2Q4YnFfTmp0T2RCNEtBOFBPZTZXQjNCOXd6a3dDM2JzSmRsak51bk93cXR4OUlEM2xzZVlBbmdkaElYZ2ltSHZMRmVNaTBPaUZmVFM1aTJCZ19ULWtjbUFfbmJQX1VrNngtNEw5d2pFRmlSSVhBTWtTb3Rz?oc=5","date":"2026-01-20","type":"regulatory","source":"Capital Brief","summary":"Telix Pharmaceuticals secures China approval for prostate cancer imaging filing - Capital Brief","headline":"Telix Pharmaceuticals secures China approval for prostate cancer imaging filing","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}